Navigation Links
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

utations in the Phase 3 PRIME Study of Panitumumab (pmab) + FOLFOX vs FOLFOX as First-line Treatment (tx) for Metastatic Colorectal Cancer (mCRC)
Abstract No. 3511, Poster Discussion, Tuesday, June 4, 8:00 a.m. CDT, S405

About Talimogene Laherparepvec
Talimogene laherparepvec is an investigational oncolytic immunotherapy derived from herpes simplex virus type-1 designed to selectively replicate within cancer cells and to produce GM-CSF to enhance systemic antitumor immune responses. Talimogene laherparepvec is injected directly into tumor tissue and replicates until the membranes of the cancer cells rupture, thereby destroying them in a process known as oncolysis. The virus contained in these cells as well as potential tumor antigens are then released locally along with GM-CSF, a white blood cell growth factor that the virus is engineered to express. This is intended to activate antigen presenting cells and elicit a systemic immune response to kill tumor cells throughout the body.

About Blinatumomab
Blinatumomab is an investigational bi-specific T cell engager (BiTE®) antibody designed to direct the body's cytotoxic T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. The modified antibodies are designed to engage two different targets simultaneously, thereby juxtaposing T cells with cancer cells. Blinatumomab is the first of the BiTE antibodies, and Amgen has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of ALL, chronic lymphocytic leukemia (CLL), hairy cell leukemia, prolymphocytic leukemia and indolent B cell lymphoma and from the European Medicines Agency for the treatment of indolent B cell lymphoma, ALL, CLL and mantle cell leukemia (MCL).

About Vectibix
Vectibix is the first fully human anti-epidermal growth factor receptor (EGFR) antibody approved b
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
2. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
3. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
4. Amgen Announces Webcast of 2013 First Quarter Financial Results
5. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
6. Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
7. Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
8. Selexis Announces Expansion of R&D License Agreement with Amgen
9. Amgen Outlines Long-Term Strategy
10. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
11. Amgen To Webcast 2013 Business Review Meeting On February 7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 CytRx Corporation (NASDAQ: ... company specializing in oncology, announced that data regarding the ... the treatment of first-line soft tissue sarcoma (STS) will ... 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting which ... Berlin , Germany. Due to the longer than expected ...
(Date:10/16/2014)... Oct. 16, 2014  Cepheid (Nasdaq: CPHD ... 2014 of $115.2 million, representing growth of 15% from ... loss in the third quarter of 2014 was $(7.2) ... loss of $(1.4) million, or $(0.02) per share, in ... stock-based compensation expense, amortization of debt discount and transaction ...
(Date:10/16/2014)... , Oct. 16, 2014   DaVita HealthCare ... one of the nation,s largest and most innovative ... Institute ranked DaVita HealthCare Partners 37 th ... recent article in Harvard Business Review ... , which evaluates companies based on reputation strength, ...
Breaking Medicine Technology:CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 2CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 3CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 4CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 5CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting 6Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Harvard Business Review Recognizes DaVita HealthCare Partners 2Harvard Business Review Recognizes DaVita HealthCare Partners 3
... 3, 2010 The Amgen Foundation will grant $4.5 million ... to invest in "LA,s Promise" – an endeavor to prepare ... college and a healthier, more successful life.   ... see an entire community,s children ready for college and life," ...
... College of Radiology (ACR) distributed 1,500 copies of the College,s ... free of charge to physicians in approximately 600 ACR-accredited mammography ... Case Review ( MCR5 ), a self-evaluation educational tool, ... detection of cancers and other abnormalities via mammography by allowing ...
Cached Medicine Technology:Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise 2Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LA's Promise 3ACR Distributes Free High-Tech Mammography Education Tool to NY Facilities 2
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Fancyflyingfox.com, an innovative company that provides many kinds of ... of 2014 mother of the bride dresses . ... with big discounts, up to 70% off. All consumers ... this special offer. , Owing to the company’s ... of the leading brands in the global market. A ...
(Date:10/19/2014)... 2014 Stephen T. Greenberg, M.D., with offices ... the 10th consecutive year as one of Long Island’s best ... also been nominated as the best provider for Botox injections. ... best Day Spa and best Laser Treatment center on Long ... readers can vote for the contest once per day, per ...
(Date:10/19/2014)... – The U.S. Government has initiated a major ... by 2025. However, a workgroup of nearly 40 ... in the U.S. Government,s National Plan to Address ... in scale, and adequately funded in order to ... by the workgroup to enlarge and strengthen the ...
(Date:10/19/2014)... One major trend in the market is ... high-cost structure leading to the implementation of more proton ... the Global Proton Therapy market to grow ... 2013-2018. According to the report, one of the main ... medical diagnostics and therapeutics. The advances in technology led ...
Breaking Medicine News(10 mins):Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 2Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 3Health News:Proton Therapy Market to Grow at 9.50% CAGR to 2018 Forecasts a New Research Report at Sandlerresearch.org 4
... The American School,Health Association, the National Association of ... today joined together to create,one voice to urge ... Prevention,and Tobacco Control Act, which would give the ... three associations, each formed to assist the Nation,s ...
... representatives are invited,to a photo opportunity with the Honourable ... Governor, in light of an,international collaboration announcement on cancer ... Convention in San Diego., Who: ... Arnold Schwarzenegger, The ...
... Inc.,(Nasdaq: HOLX ) today announced that Glenn Muir, ... Annual Healthcare Conference being,held June 24 - 26, 2008, ... Interested parties are invited to listen to a ... 25, 2008, at 12:30 PM.,Eastern Time on the investor ...
... also express concern about psoriasis drug,s possible risks for ... strengthening , , WEDNESDAY, June 18 (HealthDay News) -- ... Wednesday that the psoriasis drug Enbrel be approved for ... skin disease. , The outside medical experts, in a ...
... higher annual volumes of patients with inflammatory bowel disease ... than hospitals with lower volumes of IBD patients, according ... College of Wisconsin in Milwaukee. ,The study ... for patients who undergo surgery for Crohn,s Disease, a ...
... SF-12v2 Health Survey Results are Used to Measure Physical ... and Mental Health Status of Program Participants, ... the,SilverSneakers(R) Fitness Program was created to encourage older adults ... the nation,s leading,fitness program aimed exclusively at older adults. ...
Cached Medicine News:Health News:Major Associations Band Together to Urge Congressional Action on Tobacco Legislation 2Health News:Hologic to Present at the Jefferies 2nd Annual Healthcare Conference 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 2Health News:FDA Panel Recommends Enbrel for Pediatric Patients 3Health News:Choice of hospital impacts outcomes for inflammatory bowel disease surgery 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 2Health News:Healthways Proves Effectiveness of Senior Fitness Program with QualityMetric Health Survey 3
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... AnchorSew™ 3 mm is a resorbable repair device ... ArthroSew suturing device to attach soft tissue to ... into a prepared hole in the bone, and ... tissue anchors are made of a resorbable copolymer, ...
... is generally used when anchor size ... anchor is packaged sterile and comes ... and needles. Although pre-drilling is not ... Harpoon®, 1.6mm & 1.8mm drills are ...
Medicine Products: